Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nasser Altorki

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Plos One|August 13, 2013
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancerThomas John, Maud H W Starmans, Yao-Tseng Chen, et al.
JAMA Oncology|August 1, 2024
Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical TrialNasser Altorki, Xiaofei Wang, Bryce Damman, et al.
Lancet (London, England)|September 23, 2021
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2019
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO GuidelineBryan J Schneider, Nofisat Ismaila, Joachim Aerts, et al.
Journal for Immunotherapy of Cancer|October 30, 2023
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trialCaicun Zhou, Minu K Srivastava, Hao Xu, et al.
The New England Journal of Medicine|February 13, 2023
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung CancerNasser Altorki, Xiaofei Wang, David Kozono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancerNasser Altorki, Maureen E Lane, Thomas Bauer, et al.
The Annals of Thoracic Surgery|February 5, 2024
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung CancerElizabeth G Dunne, Cameron N Fick, James M Isbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2025
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III TrialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.
Nature|December 13, 2005
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic nicheRosandra N Kaplan, Rebecca D Riba, Stergios Zacharoulis, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Plos One|August 13, 2013
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancerThomas John, Maud H W Starmans, Yao-Tseng Chen, et al.
JAMA Oncology|August 1, 2024
Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical TrialNasser Altorki, Xiaofei Wang, Bryce Damman, et al.
Lancet (London, England)|September 23, 2021
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2019
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO GuidelineBryan J Schneider, Nofisat Ismaila, Joachim Aerts, et al.
Journal for Immunotherapy of Cancer|October 30, 2023
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trialCaicun Zhou, Minu K Srivastava, Hao Xu, et al.
The New England Journal of Medicine|February 13, 2023
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung CancerNasser Altorki, Xiaofei Wang, David Kozono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancerNasser Altorki, Maureen E Lane, Thomas Bauer, et al.
The Annals of Thoracic Surgery|February 5, 2024
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung CancerElizabeth G Dunne, Cameron N Fick, James M Isbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2025
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III TrialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.
Nature|December 13, 2005
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic nicheRosandra N Kaplan, Rebecca D Riba, Stergios Zacharoulis, et al.
Pageof 10